N Engl
J Med 2005, 352:786–792.PubMedCrossRef 19. Engelman JA, Zejnullahu K, Mitsudomi T, Song YC, Hyland C, Park JO, et al.: MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling. Science 2007, 316:1039–1043.PubMedCrossRef 20. Lustig B, Behrens J: The Wnt signaling pathway and its role in tumor development. J Cancer Res Clin Oncol 2003, 129:199–221.PubMed 21. Katoh M: WNT/PCP GDC-0068 clinical trial signaling pathway and human cancer [review]. Oncol Rep 2005, 14:1583–1588.PubMed 22. Hoschuetzky H, Aberle H, Kemler R: Beta-Catenin mediates the interaction of the cadherin-catenin complex with epidermal growth factor receptor. J Cell Biol 1994, 127:1375–1380.PubMedCrossRef 23. Suzuki M, Shigematsu H,
Nakajima T, Kubo R, Motohashi S, Sekine Y, et al.: Synchronous Alterations of Wnt and Epidermal Growth Factor Receptor Signaling Pathways through Aberrant Methylation and Selleck CB-839 Mutation in Non –Small Cell Lung Cancer. Clin Cancer Res 2007, 13:6087–6092.PubMedCrossRef 24. Therasse P, Arbuck SG, Eisenhauer EA, et al.: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000, 92:205–216.PubMedCrossRef 25. Mazieres J, He B, You L, Xu ZD, Lee AY, Mikami I, et al.: Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer. Cancer Res 2004, 64:4717–4720.PubMedCrossRef 26. Brabender J, Usadel H, Danenberg KD, Metzger R, Schneider PM, Lord RV, et al.: Adenomatous polyposis coli gene promoter hypermethylation KPT-330 in vitro in non-small cell lung cancer is associated with survival. Oncogene 2001,20(27):3528–3532.PubMedCrossRef
27. Lee SM, Kim MJ, Lee JY, Park JY, Kim DS: Aberrant methylation N-acetylglucosamine-1-phosphate transferase of E-cadherin and H-cadherin genes in non-small cell lung cancer and its relation to clinicopathologic features. Cancer 2007, 12:2785–2792. 28. Bai H, Mao L, Wang SH, Zhao J, Yang L, An TT, et al.: Epidermal Growth Factor Receptor Mutations in Plasma DNA Samples Predict Tumor Response in Chinese Patients With Stages IIIB to IV Non–Small-Cell Lung Cancer. J Clin Oncol 2009, 27:2653–2659.PubMedCrossRef 29. Griffiths EA, Gore SD, Hooker C, McDevitt MA, Karp JE, Smith BD, et al.: Acute myeloid leukemia is characterized by Wnt pathway inhibitor promoter hypermethylation. Leuk Lymphoma 2010,51(9):1711–1719.PubMedCrossRef 30. Su HY, Lai HC, Lin YW, Liu VY, Chen CK, Chou YC, et al.: Epigenetic silencing of SFRP5 is related to malignant phenotype and chemoresistance of ovarian cancer through Wnt signaling pathway. Int J Cancer 2010,127(3):555–567.PubMedCrossRef 31. Zhao C, Bu X, Zhang N, Wang W: Downregulation of SFRP5 expression and its inverse correlation with those of MMP-7 and MT1-MMP in gastric cancer. BMC Cancer 2009, 9:224.PubMedCrossRef 32. Sogabe Y, Suzuki H, Toyota M, Ogi K, Imai T, Nojima M, et al.: Epigenetic inactivation of SFRP genes in oral squamous cell carcinoma. Int J Oncol 2008,32(6):1253–1261.PubMed 33.
Related posts:
- J Immunol Methods 2005, 298: 61–72 PubMedCrossRef 19 Lin W, Vosk
- PubMedCrossRef 15 Turashvili G, Bouchal J, Burkadze G, Kolar Z:
- Cancer Res 2007, 67:4725–4731 PubMedCrossRef 28 Wente MN, Gaida
- Mol Cell Biochem 2006, 286: 67–76 PubMedCrossRef 13 Fong WG, Lis
- J Cell Physiol 2006, 207:520–529 PubMedCrossRef
8 Caloge